Kurse werden geladen...
Prognose
| Kaufen | 1 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey.» Mehr auf globenewswire.com
AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis Research
SAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (Nasdaq: ICU) announced today that a new United States Department of Defense (DoD) grant has been awarded to AREVA. The grant is one of four selected out of 160 total submissions by the 2024 Military Burn Research Program (MBRP) and represents cutting-edge research for extracorporeal immunomodulation to reduce inflammation after severe burns, inhalation injury, and septicemia.» Mehr auf globenewswire.com
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
Coverage marks SeaStar Medical's second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 270,84k | - |
| Bruttoeinkommen | 270,84k | - |
| Nettoeinkommen | −3,49 Mio | 70,36% |
| EBITDA | −3,47 Mio | 70,14% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 10,57 Mio€ |
Anzahl Aktien | 10,36 Mio |
52 Wochen-Hoch/Tief | 11,98€ - 0,96€ |
| Dividenden | Nein |
Beta | -0,86 |
KGV (PE Ratio) | −0,64 |
KGWV (PEG Ratio) | −0,01 |
KBV (PB Ratio) | 18,00 |
KUV (PS Ratio) | 28,55 |
Unternehmensprofil
| Name | SeaStar Medical Holding Corp Ordinary Shares |
| CEO | Eric Schlorff |
| Mitarbeiter | 19 |
Assets entdecken
Shareholder von SeaStar Medical Holding Corp Ordinary Shares investieren auch in folgende Assets
